Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Ronopterin (Primary)
- Indications Brain injuries
- Focus Registrational; Therapeutic Use
- Acronyms NOSTRA-III
- Sponsors vasopharm BIOTECH
- 06 Sep 2016 According to a Vasopharm media release, data read-out (final clinical report) of the study is estimated for mid-2019.
- 06 Sep 2016 According to a vasopharm media release, first patient has been enrolled in this trial.
- 06 Sep 2016 Planned number of patients changed from 220 to 232, according to a Vasopharm media release.